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Abstract
Increasing focus on issues of research reproducibility affords us the opportunity to review some of the key issues related in
vivo research. First, we set out some key definitions, to guide the reader through the rest of the paper. Next we consider
issues of epistemology, of how animal experiments lead to changes in our understanding of biomedicine and, potentially, to
the development of new therapeutics. Here we consider the meaning of statistical significance; the importance of
understanding whether findings have general truth; and the advances in knowledge which can result from ‘failed’
replication. Then, we consider weaknesses in the design, conduct and reporting of experiments, and review evidence for this
from systematic reviews and from experimental studies addressing these issues. We consider the impact that these
weaknesses have on the development of new treatments for human disease, and reflect on the response to these issues
from the biomedical research community. Finally, we consider strategies for improvement including increased use of brief,
pre-registered study protocols; pre-registration, open publication and open data; and the central importance of education in
improving research performance.
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Introduction
Definitions of Reproducibility and Rigor
It is important for research users to know how likely it is that
reported research findings are true. Early definitions of ‘repro-
ducibility’ related to the reanalysis of existing data following the
same analytical procedures. ‘Replication’ was held to require the
collection of new data, following the same methods, and apply-
ing the same analytical procedures. However, the interchange-
able use of these terms (and others) is such that ‘reproducible
research’ has come to have broader meaning than perhaps ini-
tially intended [1].
Articulating this broader definition, and borrowing from
Goodman [1], one might consider a hierarchy of characteristics
that might give confidence in the ‘truth’ of a research finding:
first, ‘reproducibility’ as originally described, based on reanalysis
of an existing dataset (‘reproducibility of analysis’); secondly, the
collection of new data in experiments as identical as possible to
the first (‘reproducibility of experimental findings’); and thirdly,
the deliberate variation of experimental conditions or analytical
approaches to establish whether the same conclusions can
be drawn (‘robustness’). Goodman considers 2 more levels:
inferential reproducibility (making the same evidentiary claims
for the same analytical findings) and generalizability (the extent
to which predictions made by experiments are true outside of a
research or laboratory setting; Figure 1).
The main focus of recent concern relates to reproducibility
of experimental findings. This has been studied in retrospective
observational [2,3] and prospective [4] studies. In these projects,
it was not possible to confirm many findings previously consid-
ered to be ‘true’. For instance, the recent Many Labs 2 replication
project successfully replicated only 54% of findings [5]. The Can-
cer Biology Replication project found several instances of failed
replication, including no evidence that Fusobacterium nucleatum
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Figure 1: Definitions in reproducibility and replication.
was prevalent in human colonic carcinoma [6], in contrast to a
highly cited previous report that it might be causally related to
the development of cancer [7].
Failed replication (“reproducibility of experimental findings”)
in biomedical research may occur if the originator study was
falsely positive (by chance or because the internal validity of the
study was reduced because the experimental design placed the
study at risk of bias); if our understanding of the literature is
polluted by publication bias; or in the presence of someunknown
(latent) independent variable that influences the phenomenon
under study. In this last case, what was intended as a test of
replication of experimental findings was in fact an inadvertent
test of robustness. Identifying the nature of such previously
latent factors that influence the biological phenomena observed
might lead to better understanding of the mechanisms being
studied. Finally, it may be that our understanding, drawn from
the literature, is confounded by publication bias. That is, the
reports in the literature represent experiments where an effect
was observed by chance but similar experiments where no effect
was observed were never published (publication bias [8,9]).
Sensible responses to failed replication might firstly seek to
increase the probability that published research is true (through
the development of organized research improvement strate-
gies [10]). Next, we might establish a framework to select effi-
ciently which research findings we should attempt to replicate
(by establishing if there are study characteristics that predict
whether a research finding can be replicated). Next, we could
develop strategies to evaluate the robustness of key research
findings (based on pre-registered, probably multicenter studies,
with deliberate heterogeneity). This would provide an opportu-
nity to substantially increase the value of existing and future
research. Finally, adoption of animal study registries (such as
preclinicaltrials.eu and animalstudyregistry.org) and the Regis-
tered Reports format (see, eg, https://openscience.bmj.com/page
s/registered-reports-guidelines/) would do much to address the
problem of publication bias.
Epistemology: How Do We Know What We Know?
What Does Statistical SignificanceMean? Interpretation of exper-
imental findings often gives cause for concern;many newspaper
journalists (and some scientists) believe that a finding at P< .05
can be considered ‘proven’. However, given low statistical power
and an observation that might transform our biological under-
standing, the positive predictive value of such a finding may
be very low indeed [11]. A recent supplement to The American
Statistician explores these issues in greater depth than is possible
here [12]. Where journals and individuals place a premium on
novelty, the prior is by definition low, and so for a given statistical
power and P value the chances of such findings being true
are lower than they are for more ordinary research findings.
Various prediction markets employed in the context of formal
replication projects give approximate ‘priors’, derived from the
findings of the originator study and the expert assessment of
the credibility of those findings. From these, and the statistical
power of the replication efforts, one can derive an estimate of
the number of studies that will not replicate. For 41 studies
in the Psychology Replication Project, the expected number of
failed replications was 19 against an observed number of 25 [13].
From this, we can surmise that much of the replication crisis (at
least in psychology) arises because of a tendency to accept the
findings of such originator studies without acknowledging that
the strength of evidence provided may actually be rather low. It
seems that scientists, like everyone, love a good story.
From the Specific to the General In the context of in vivo mod-
els of human disease, the important considerations are firstly
the reproducibility of experimental findings, and secondly their
robustness. That is, firstly, can others observe the same effect
under the same conditions? Secondly, is the effect observed
under a suitably wide range of biologically relevant circum-
stances?
The exploitation of biomedical research for health gain
passes through different domains, usually (but not always)
startingwith in vitro research and culminating in human clinical
trials. At each transition, a judgement is made about whether
the accumulated evidence is enough to justify that transition or
whether further research in the current domain is required. The
etymology of the term ‘translation’ refers to ‘across from’ and
‘to carry’, hence, the carrying across of research findings from
1 domain to another. We might also consider the process of
conducting further research in the same domain, seeking more
persuasive evidence before attempting translation. Using the
same etymology, this might be described as “cis-lation,” derived
from ‘on the side of’ and ‘to carry,’ tomean the re-use of research
findings in the same domain.
At each juncture, there is a choice to embark on translation
or cis-lation; translate too early, and research in the next domain
is based on an insufficiently complete understanding of in vivo
biology, and so is at greater risk of failure. The ethical conduct
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of all research requires consideration of the potential harms
to research participants and the potential benefits from the
knowledge that might be gained; the ethical status of research
that is not well founded is diminished. Equally, translate too
late, and further research conducted in the current domain is
unnecessary, and the harms to laboratory animals and the costs
of conducting research are not balanced bymaximization of ben-
efits from that research. The key consideration is the marginal
utility of the next research investment—will we learnmore from
translation or cis-lation?
Is ‘Failed’ Replication Always a Bad Thing? Does the problem of
failed replication mean that science is in crisis? If the failure to
reproduce experimental findings were due to widely prevalent
problems with originator experiments (risks of bias, or selective
publication of positive findings, or flexibility in data analysis),
this would indeed be a problem; this is discussed in detail
below. However, themany biological variables that might impact
observed outcomes and the limited reporting of even the most
obvious of these (sex of the animal, housing conditions, cir-
cumstances of testing) make attempted reproducibility of many
experimental findings difficult, if not impossible. Further, given
the opportunities for important variables (eg, source of chow,
ventilation, ambient noise) to differ unpredictably between lab-
oratories, it is likely that many attempts at replication of experi-
mental findings are in fact tests of robustness because of varia-
tion in latent independent variables differently represented in
different research environments. This has been described by
Voekl and Würbel [14]. Importantly, it follows that these latent
independent variables are inducing important but unexplained
biological effects, and attempts to better understand how this
happens are likely to lead to increased understanding of basic
biology.
For instance, the failure to replicate drug effects on extending
lifespan in worms led initially to despair but, many years later,
inspired the multicenter US National Institute on Aging (NIA)-
funded Caenorhabditis Intervention Testing Program. [15] After
much effort, the authors were able to show bimodal patterns of
worm survival (some long lifespan, some short), with different
strains falling into different survival categories in different labs.
They could not explain these differences through any known
biology. [16] This has provided a starting point for research that
should deepen our understanding of the biology of ageing.
Weaknesses in the Design, Conduct, and Reporting of
Experiments
There are some features of study design—such as the study
population, interventions, and outcomes measured—that are so
fundamental to understanding what was done, and to inter-
preting the findings, that they should be adequately described.
Researchers should report all of their findings, not ‘cherry-pick’
the ones that are most interesting or favorable to their hypothe-
sis.They should choose their statistical tests carefully at the time
of conception of experiments and not subject the same data to
multiple transformations and tests until they yield the desired
answer (ie, p-hacking). They should articulate a hypothesis and
then design an experiment to test it rather than developing a
hypothesis to explain a series of observations and then claiming
that this was the hypothesis they tested. This is also true—
perhaps especially true—for observational studies seeking pos-
sible associations between certain characteristics and observed
outcomes, where the risks of identifying spurious associations
are high.
Risks of Bias Identified Through Systematic Reviews Systematic
reviews in clinical medicine (as championed by the Cochrane
Collaboration [17]) conventionally include an assessment of risks
of bias in contributing studies. This practice has been adopted
by systematic reviews of in vivo studies (ie, basic science), with
reviewers recording whether a given study reports important
aspects of experimental design. Thesemay be general aspects of
experimental design (such as randomization or blinding) or spe-
cific to the research field (for instance, a statement of control of
body temperature in focal ischemia experiments). Importantly,
these are (at least initially) aspects of study design that those
conducting systematic reviews claim to be important, where
they believe that studies not done to that standard are at risk
of giving erroneous results. Further, it may be that although
a publication does not describe blinding, this was in fact per-
formed by the investigators but not reported (due for instance
to limitations of space in manuscripts). However, where authors
have been required to report whether they have blinded, there is
only a small increase in prevalence. [18] This suggests that the
problem is not with nonreporting but with blinding not having
been performed.
In ameta-analysis, it is possible to group studies according to
whether they did or did not report aspects of study design that
might reduce the risk of bias (such as randomization or blinding)
and to observe whether these groups of studies give different
estimates of biological effect. This approach has somewhat lim-
ited statistical power [19], but across a range ofmodels of various
diseases we and others have shown higher reported efficacy in
studies that do not report the blinded assessment of outcome,
random allocation to group, blinded conduct of the experiment,
or a sample size calculation [20–23].
Coupled with high prior beliefs that these issues are
important, along with evidence from other research domains,
there is now a consensus that, where possible, scientists
should adopt these practices to reduce the risks of bias in
their work (in some situations—such as observing behavior in
transgenic animals with obvious differences in body habitus—
this should be discussed as a limitation). This consensus has
been reflected in several key recommendations including those
from an NIH consensus panel [24], the ARRIVE guidelines [25],
the US National Research Council, [26] and from the Nature
Publication Group (NPG) [27]. For instance, the Landis guidelines
recommend that investigators should report on randomization,
blinding, sample size calculations, and animals excluded from
analysis. Generally, the broader the group that developed the
guidelines, the greater their range of applicability and the greater
their impact.
Impact of Risks of Bias in Studies Using Laboratory Animals
Identified Through Systematic Reviews To really understand the
impact of bias in animal studies, we would need to do a series
of studies, some at risk of bias and others not, and compare the
findings. For instance, a series of studies could be randomized
to be conducted either blinded or not—would the results be any
different? However, the design of such research on research is
challenging. The researchers conducting the individual studies
would need to be unaware of the true purpose of the project
(lest this impacted their behavior), and this makes recruitment,
and issues of consent, difficult. It might be possible to test the
impact of training programs for researchers, but this raises
ethical concerns about potential harms done to experimental
subjects where the investigator had been randomized to the
control group.
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In the early 1960s Rosenthal and Fode explored the impact of
investigator expectations on tests of maze performance in rats
[28]. They had graduate students conduct experiments where
the students were led to believe that 2 cohorts of rats would have
very different performance. The students did indeed observe
such differences, but in fact the rats were identical and had
been allocated to these different groups at random.The observed
differences between the groups were consequently an effect of
the observers’ expectations and unintentional bias.
These findings are supported by a systematic review of
10 studies where outcome was assessed by both blinded and
unblinded observers [29]; the observed effects were 59% greater
in the unblinded studies.
Despite evidence from both observational and experimental
studies, the quality of published scientific works as measured
against relevant guidelines for reporting (for instance random-
ization and blinding) remains low. In a random sample of publi-
cations from PubMed published between 2008 and 2012, report-
ing of randomization was 33% and reporting of whether asses-
sors were blinded to experimental group was only 7% [30]. In
work from leading UK institutions (as determined by a national
research assessment exercise) published in 2009 and 2010, only
1 of 1172 manuscripts reported whether experiments were ran-
domized or blinded were designed on the basis of a sample size
calculation and described criteria for excluding animals from
analysis; 68% reported none of these things [31].
What Are the Costs and Consequences of Poor Practice? Scientific
findings may never be used, be used to inform further research,
or be used to inform changes in policy or practice. Where a
scientific literature informs further research, it is important that
that information is reliable; it is important for research users to
know how likely it is that reported research findings are true.
Where further research is planned based on flawed findings,
the costs are propagated to that new research, which has a
much lower chance of succeeding. The NXY059 clinical trial
program in stroke was based on data from animal studies that,
with the benefit of hindsight, were unreliable—most studies did
not report randomization or blinding of investigators during the
experiment or when assessing outcome. The NXY059 clinical
trial program involved some 5500 patients, cost millions of dol-
lars, and the publication of the statistically neutral results of the
SAINT II trial [32] was associated with a substantial decrease
in the market capitalization of the pharmaceutical company
concerned. More recently, the development of a new vaccine
for tuberculosis has been criticized on the grounds that the
animal studies on which it was based were at substantial risks
of bias [33]. The costs of failure were again high. The severe
adverse effects experienced by participants in the phase I clinical
study of the humanized monoclonal CD-28 agonist have been
attributed to insufficient research done on the translatability
of results between species (ie, from nonhuman primates to
humans), specifically in the difference in mechanism of action
of the study drug at the cellular level [34]. In each case, trial
participants were exposed to potential harms in a context where
the suggested benefits were less than predicted, because the
premise for the trials was flawed.
The Community Response Interestingly, efforts to improve the
conduct and reporting of animal research have met with some
resistance, often from unexpected quarters. For instance, in 2015
the president of FASEB argued that guidelines introduced by the
US National Institutes of Health were
. . . premature, ..(lacked) the appropriate flexibility to be appli-
cable across disciplines, and (were) likely (to) produce significant
and in some cases unjustified burden associated with the prepa-
ration and review of scientific manuscripts. [35]
In a context where it has been argued that as much as 85%
of the $300bn annual investment in biomedical research may
be wasted [36] and where only 1 of over 1000 studies from
leading UK institutions reported key aspects of study design
[37], this seems at face value to have been an unusual although
not a unique response. In fact, and in contrast to the reserva-
tions expressed above, FASEB has played an important role in
addressing these issues, for instance in their Transparency and
Rigor Initiative and their recommendations Enhancing Research
Reproducibility. [38]
Institutional efforts have largely focused on the response to
deliberate and unacceptable attempts by researchers to subvert
the integrity of the scientific process. Such actions include falsi-
fication, fabrication, and plagiarism. [39]
One might consider the quality and rigor of research to exist
in a spectrum, from these most egregious practices at one end,
then through for instance the practice of hypothesizing after
results are known (HARKing) and conducting research at risks of
bias, to research of higher quality defined for instance by adop-
tion of open science practices and the use of Registered Reports
(Figure 2a). An institutional focus on worst practice (Figure 2b)
might mean that efforts in research improvement are negatively
perceived by researchers, being associated with a small group of
malfeasant individuals rather than being something of relevance
to all researchers.
Rather, the emphasis might more usefully be on improve-
ment (Figure 2c).Nomatter howeffective and rigorous a scientist
is, there will always be room for some improvement, that they
may become even better. If community efforts to address these
issues were to improve everyone’s performance even by a small
amount, the impact on the value that accrues from biomedical
research would be substantial.
Strategies to Improve Performance
Much effort has been expended on the development and imple-
mentation of guidelines for the design, conduct, and reporting
of in vivo research. These now include the PREPARE guide-
lines [40], the ARRIVE guidelines [25], field-specific guidelines
such as those for in vivo stroke research [41,42], journal-specific
guidelines such as those introduced by Nature Publishing Group
[27], and guidelines articulated by community groups. Given
improvements in the conduct and reporting of clinical research,
it was hoped that they would have a similar effect for in vivo
research. The reality is more nuanced. It appears that the devel-
opment, articulation, and endorsement of such guidelines, in
and of itself, may do very little to improve performance; more
sophisticated implementation strategies may be required. This
may involve prioritizing those factors that are considered essen-
tial from those that are highly desirable.
Following publication of good laboratory practice guidelines
for stroke research, a major journal in the field changed their
peer review web platform to require reviewers to assess report-
ing of keymeasures to reduce the risks of bias.Over the following
4 years, reporting of design features such as randomization and
blinding in manuscripts in that journal improved substantially,
[43] and, critically, no improvement was seen in the reporting
of animal research in 4 other journals from the same publisher
even when adjusted for the disease under study and the species
of animal used [44]. Some research domains seem to experience
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Figure 2: Illustrative histogram of the distribution of research behaviors. (a)
Research practices defining points on the distribution. FFP = Falsification, Fab-
rication, and Plagiarism; HARKing = hypothesizing after results are known. (b)
Spotlight on the most egregious practices. (c) Alternative strategy of shifting
distribution of performance to higher level (move from gold to blue line).
greater challenges in translation, [45] perhaps because potential
treatment effects are smaller or take longer to becomemanifest,
but rigorous approaches to research are in our view important in
increasing value across all research domains.
In 2013 the NPG introduced a new checklist for reporting in
vivo research, based in part on the Landis criteria [27]. We have
measured compliance with that checklist in NPG publications
before and after the change in policy in the Nature Publications
Quality In Publication (NPQIP) study and found a substantial
increase in the proportion of studies reporting each of random-
ization, blinding, sample size calculations, and details of animal
excluded from analysis. The proportion of studies reporting
all of these increased from zero to 16%. In matched articles
from non-NPG sources no improvement was seen. NPG editorial
staff report making substantial efforts for each manuscript to
maximize compliance, a process facilitated by the iterative and
detailed review process occurring at those journals. In contrast,
Baker et al reported that, 2 years after adoption of the ARRIVE
checklist at PLoS, there had been little if any improvement in
performance [46]. It was argued that journals need to do more
to encourage guideline compliance, but in a randomized con-
trolled study (IICARUS) we showed that even a requirement for
submission of a completed ARRIVE checklist had no effect on the
completeness of reporting of the ARRIVE items, being 0% in both
the intervention and control groups [47,48].
Importantly, in both NPQIP and IICARUS, outcome assess-
ments were performed in duplicate by at least 2 trained asses-
sors, with differences reconciled by a third. This gives the oppor-
tunity to study the inter-observer agreement in the assessment
of each of the checklist items, and we found that for some items
agreement was no greater than would be expected by chance
alone. This implies either that the wording of the checklist item
was not sufficiently clear or that the underlying concept was
not well understood even by trained assessors, or both. Although
these checklists were developed by eminent and well-informed
groups, this draws attention to the importance of testing guide-
lines under development for their in-use characteristics—that
is, are the concepts articulated in such a way that informed
scientists are able to agree onwhether amanuscript does or does
not meet the requirements of a checklist item?
Rigor in Animal Research in the Context of Rigor in Other Research
Domains Animal research is by no means the only research
domain that has been challenged by a replication crisis. Indeed,
difficulties in replication have been observed in every field in
which it has been studied. It is therefore reasonable to assume
that it this a general feature of research of all kinds and animal
researchers are not in any way unusual in experiencing diffi-
culties in replication. Indeed, the NPQIP study suggested that in
the in vitro literature, risks of bias were addressed much less
frequently than was the case in the in vivo literature. As well
as raising concerns for the development of non-animal alterna-
tives, this sets the current performance of animal researchers
in a more nuanced context, while accepting that research stake-
holders in every domain should be seeking to improve the relia-
bility of the work with which they are associated.
Ex Ante Statements of Experimental Intent One simple approach
to improving the provenance of animal research is for investiga-
tors to assert, in advance, key aspects of their study. This might
be accomplished using the Registered Report framework dis-
cussed above, or made available online, with the possibility (for
instance on the web pages of the Open Science Framework) of it
remaining private until a time of the author’s choosing. The level
of detail to include is a matter for the individual investigator,
but we have suggested that at a minimum it include the study
population, hypothesis, intervention, statistical analysis plan,
primary outcome measure, and sample size calculation [49].
Research plans often change—appropriately—due to unforeseen
circumstances. The existence of an a priori study protocol allows
the research user to understand what those changes have been
and allows the researcher to explain why the change was made.
Of course, the more detailed the protocol, the greater the
protection afforded. An analysis plan that clearly describes the
criteria for removing an animal from analysis is better than one
that vaguely states they will remove animals where induction of
the lesion has been unsuccessful. Wicherts et al have helpfully
articulated 34 researcher degrees of freedom that should be con-
strained in a good study such as establishment of inclusion/ex-
clusion criteria, defining outliers, and describing limitations and
caveats of the study.
Preregistration, Open Publication, and Open Data In the context
of in vivo research, previous publication models were limited
by word count limits and page charges, which meant that for
most publications the information provided was at best a precis
of what had been done, condensed into the smallest possible
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space. Demonstration of being the first to study and report a
phenomenon was based on the date of submission or publica-
tion, and authors were understandably unwilling to share their
ideas until they could establish primacy. As a result, they did
not share research plans in advance, and the course of their
study could only be established by inspection of signed and
dated laboratory notebooks. Work was published months or
years after the analyses were complete, following several rounds
of peer review, a process often repeated at several journals until
a home for the work was found. If the intention of (at least some)
research is to contribute to treatments for human disease, these
delays are measured in human death and disability. Often when
work was published, only summary data were available, often
only in graphical form, precluding for instance fruitful reuse and
reanalysis.We are now in the fortunate position of having online
tools that remove all of these barriers, but uptake of these tools
is, to date, very slow.
Specifically, the Open Science Framework provides amedium
for the confidential deposition of study-related materials, with
date of accession recorded, so that these can at a later time
point be made public, with a permanent digital object identifier
(DOI) locator, at the time of the investigator’s choosing. The
development of preprint servers where work can be shared
publically before peer review (eg, BioRxiv, www.biorxiv.org) and
online journals offering post publication peer review allows
research findings to be placed in the public domain—with a
DOI and visible to indexing services such as Google Scholar—
within days of submission. Finally, data archiving tools such as
Figshare (www.figshare.org) allow scientists to make available
entire complex datasets onwhich they have based their findings,
again with a DOI. That these tools fill an important unmet need
is not in doubt.
Challenge of Education There are now many, largely local initia-
tives seeking to improve research performance, and this is very
much to be welcomed. The focus of most begins with efforts
to provide education and training to scientists that they might
improve their performance. However, scientific research is a
complex ecosystem, and behavioral change will require more
than education. Michie [50] has identified common themes in
the behavioral change literature, articulated as a requirement
that individuals have the capability, opportunity, and motiva-
tion to do things differently. It is likely, therefore, that research
improvement will require complex interventions, and develop-
ing and validating these may well be beyond the capability of
many research institutions. It would be desirable, therefore, if
there were established some larger coalition of institutions, fun-
ders, and journals who could work together to establish which
interventions work best in which circumstances and to provide
support for research stakeholders embarking on improvement
activity.
Conclusions
Increasing Ethics by Increasing Benefits
To be ethical, researchers need to demonstrate a positive benefit-
harm calculus for their proposed work. For in vivo research,
this has classically been approached through efforts to reduce
harms experienced by experimental subjects, largely through
the application of the three Rs, Russel and Burch’s principles that
scientific procedures should be carried out with replacement
of animals where this is possible, reduction in the numbers
of animals used, and refinement of techniques to minimize
harms to the animals. In the context of the 3Rs, the benefits
accruing from research have largely been taken as self-evident
or evidenced by the fact that a funding agency has considered
thework to have value.An alternative approach (complementary
to reducing harm), with widespread potential application, is to
improve the ethical position of research by taking reasonable
efforts to increase benefit, as described above, by increasing the
value and reliability of research findings.
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